ALSO NOTED: Pre-emption fears helped spur Zyprexa deal; U.K. implant makers charge U.S. market;

> Scratching your head over the Zyprexa settlement in Alaska? Apparently, the prospect of a Supreme Court ruling that might sweep away state pharma suits helped spur the agreement. Report

> Newfangled hip implants from British device makers Smith & Nephew and Corin are going head-to-head in a battle for market share in the U.S. Report

> A New Jersey legislator is asking the state's attorney general to investigate the use of antipsychotic meds in children; over the past seven years, New Jersey Medicaid spent more than $73 million on the drugs for kids less than 18 years old, even though they're not approved by the FDA for pediatric use. Report

> Pfizer plans to set up a new regional headquarters in Dubai, using the facility as a hub for operations in the Middle East and Africa. Report

> PharmAthene is making a bid to develop a next-gen anthrax vaccine that can qualify for a $400 million government contract. Report

> Is a rising tide of risk aversion at a post-Vioxx FDA behind the agency's anemic approval record? No way, say the FDA's Janet Woodcock (photo). Report

> Drug developers say politics are behind slow approval process. Report

> In Vivo says that biotech investors haven't proven to be very bullish about the money that pharma companies are pumping into emerging developers through new collaborations. Report

> New Jersey officials want to expand the state's biopharma business. Report

And Finally... After trying and failing repeatedly to develop an AIDS vaccine, federal officials say they're going back to the drawing board to come up with some new ideas. Report

Suggested Articles

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.